Context: MicroRNAs (miRNAs) are strongly implicated in many cancers, including papillary thyroid carcinoma (PTC), which is the most common malignancy in thyroid tissue. Recently, miRNA-155 (miR-155) has been proved to play a substantial role in liposarcoma and breast cancer, but its functions in the context of PTC remain unknown.
RET/PTC rearrangements (4), the BRAF point mutation (3) , and, less frequently, RAS mutations (5) . Recently, Santoro and colleagues (6) showed that RET/PTC stimulates the ␤-catenin pathway and promotes cell proliferation of PTC, suggesting ␤-catenin signaling may play a substantial role in the development and progression of PTC.
␤-Catenin, a key downstream transcriptional activator of the Wnt signaling pathway, plays essential roles in tumorigenesis (7) (8) (9) (10) . In the absence of Wnt, cytoplasmic ␤-catenin is constantly degraded by a protein complex called destruction complex, which is composed of adenomatous polyposis coli (APC), glycogen synthase kinase 3 (GSK3)␤, Axin, and casein kinase 1␣ (CK1␣) (11) . However, activation of Wnt signaling disrupts this destruction complex, which enables ␤-catenin stabilization, cytoplasmic accumulation, and finally translocation to the nucleus. Once inside the nucleus, ␤-catenin interacts with the transcription factor lymphoid enhancer-binding factor 1 (LEF)/T cell-specific transcription factor (TCF) to activate target gene transcription, which are important for cell proliferation, differentiation, and apoptosis (7) (8) (9) (10) .
MicroRNAs (miRNAs) are a class of 22-nucleotide, endogenous, noncoding RNAs that function as critical gene regulators. Each miRNA regulates hundreds of target genes, underscoring the potential influences of miRNAs on almost every biological pathway (12, 13) . Accumulated studies indicate that miRNAs function to regulate tumor growth and metastasis and are considered promising targets for the diagnosis and prognosis of a number of cancers, including hepatocellular carcinoma (14) , breast cancer (15) , and prostate cancer (16) . However, the potential implication of miRNAs in the tumorigenesis of PTC remains largely unknown. To date, only a few human miRNAs have been shown to be dysregulated in PTC, including miR-886-3p, miR-129-5p, and miR-146-5p (13, (17) (18) (19) , which contribute to the development and progression of PTC. Among them, miR-155 attracts much attention because it functions as an oncogenic miRNA in many human cancers (20, 21) . Several studies have shown that miR-155 is upregulated in thyroid tumors (22, 23) ; however, to our knowledge, no functional evidence of miR-155 in PTC has been documented.
In this study, we investigated the potential involvement of miR-155 in PTC. We hypothesized that miR-155 could promote tumor growth of PTC by targeted regulating APC expression and activating the Wnt/␤-catenin signaling. Our study will provide a better understanding of PTC pathogenesis.
Materials and Methods

Tissue specimens and cell lines
Twenty pairs of human PTC and adjacent normal tissues were obtained from Shanghai 10th People's Hospital (Shanghai, China). The tissues were frozen in liquid nitrogen and stored at Ϫ80°C until use. All tumors were reviewed by a single pathologist and classified according to the widely accepted diagnostic histologic criteria (24) . Written informed consent for tissue donation (for research purposes) was obtained from the patients, and the protocol was approved by the Institutional Review Board of Shanghai 10th People's Hospital and Tongji University. Human HEK293T cells, human PTC cell lines TPC-1 (Shanghai Ruiqi Biological Technology Co, Ltd, Shanghai, China), CGTH-W3 (25), K1 (Institute of Biochemistry and Cell Biology, SIBS, CAS, Shanghai, China), IHH-4 (26), the human thyroid epithelial cell line Nthy-ori3-1 (Shanghai Edinburgh Biological Science and Technology Development Co, Ltd, Shanghai, China), and noncancerous human thyroid epithelial cells (TECs) (27) were cultured in DMEM plus 10% fetal bovine serum (Life Technologies, Inc, Grand Island, New York) at 37°C in a humidified atmosphere containing 5% CO 2 . The CGTH-W3 cell line was a generous gift from Dr Jen-Der Lin (Chang Gung Memorial Hospital, Taiwan), The IHH-4 cell line was obtained from Health Science Research Resources Bank (Osaka, Japan) and was established from a 75-year-old man with a PTC, The TECs were isolated from adjacent normal thyroid tissue according to the method described previously in detail (27) . Authentication of normal thyrocyte and PTC cells cultured was provided using the short tandem repeat profiling (for the methods and results see in the Supplemental Data "Cell Authentication" and Supplemental Figure 1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
RNA extraction and quantitative real-time PCR
Total RNA was extracted using the TRIzol reagent (Life Technologies) according to the manufacturer's protocol. The RT-PCR primers for miR-155 and U6 were purchased from RiBoBio (Guangzhou, China). The PCR primers for APC were 5Ј-CCA CAG GCA AAT CCT AAG AGA GAA C-3Ј and 5Ј-ATT GTC AAA AGT TTC TGA TAA GTG C-3Ј. cDNA was synthesized from 1 g total RNA with a reverse reaction kit (Promega, Madison, Wisconsin). The melting curves were used to confirm the specificity of (PCR) amplification. Realtime PCR was performed using SYBR Premix Ex Taq II (TaKaRa, Da-Liang, China). Expression of U6 or ␤-actin was used as internal control. The relative expression levels of each gene was calculated and normalized using the 2
Ϫ⌬⌬Ct method relative to ␤-actin or U6 small nuclear RNA. All of the reactions were run in triplicate.
Lentivirus production and infection
The pre-miR-155 sequence was amplified and cloned into the lentivirus-based expression plasmid pCDH-CMV-MCS-EF1-coGFP constructs (System Biosciences, Mountain View, California). The primers for pre-miR-155 were 5Ј-CCA GAA TTC TCT GAG TGC TGA AGG CTT GCT GTA G-3Ј (forward) and 5Ј-CAC GGA TCC TGA AGT CTA AGT TTA TCC AGC AGG G-3Ј (reverse). Virus particles were harvested 48 hours after pCDH-CMV-miR-155 transfection with the packaging plas-mids pRSV/pREV, pCMV/pVSVG, and pMDLG/pRRE into 293T cells using Lipofectamine 2000 reagent (Life Technologies). TPC-1 and CGTH-W3 cells were infected with recombinant lentivirus-transducing units plus 10 g/mL polybrene (Sigma, St Louis, Missouri).
Oligonucleotide transfection
The APC small interfering RNA (siRNA) and ␤-catenin siRNA were purchased from GeneChem (Shanghai, China). The miR-155 inhibitor antimiR-155 were obtained from Ambion (Austin, Texas). Target cells were transfected with anti-miR-155, APC siRNA, or ␤-catenin siRNA using Lipofectamine 2000 (Life Technologies) according to the manufacturer's protocol. Cells were collected 48 hours after transfection.
Plasmid construction
The coding sequences of APC were amplified and cloned into pcDNA3.1(ϩ) to generate APC expression vectors. The primers for APC were 5Ј-GGA TCC GAT GGC TGC AGC TTC ATA TGA TCA GTT GTT-3Ј (forward) and 5Ј-GCG GCC GCT TAA ACA GAT GTC ACA AGG TAA GAC CCA GA-3Ј (reverse). The full-length APC 3Ј-untranslated region (UTR) was cloned into pGL3 luciferase vector (Ambion). The luc-mut vector, in which the first 5 nucleotides complementary to the miR-155 seed region were mutated by site-directed mutagenesis, was constructed as a mutant control. The primers for APC 3Ј-UTR were 5Ј-GGG TAC CCG GAG GCA CTC TTG ATG GTT AGG-3Ј (forward) and 5Ј-CCT CGG TAA AGC AAA GCA GGC TGG GTA A-3Ј (reverse).
Luciferase reporter assay
TPC-1 and CGTH-W3 cells were seeded in 24-well plates and transiently transfected with appropriate reporter plasmid and miRNA using Lipofectamine 2000. After 48 hours, the cells were harvested and lysed, and luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega). Renilla luciferase was used for normalization. The experiments were performed independently in triplicate.
Cell viability analysis
To evaluate cell viability, 2 ϫ 10 3 cells were separately plated in 96-well plates. After transfection, cell viability was identified using methylthiazoletetrazolium (MTT) assay. Briefly, 20 l of an MTT dye solution (5 mg/mL; Sigma) was added to each well and continued incubation for 4 hours. Then, the supernatant was removed and 150 l dimethylsulfoxide was added to stop the reaction. Finally, the OD was determined with a microplate spectrophotometer (ELx800; Bio-TEK, Win- ooski, Vermont) at a wavelength of 570 nm, and the viability curve was generated based on absorbance and time.
Colony formation assay
Cells were infected with miR-155-lentivirus to stably overexpress miR-155. After 48 hours of infection, the cells were plated in 6-well plates at 200 per well and grown for 2 weeks. After 2 weeks, the cells were washed twice with PBS, fixed with methanol/acetic acid (3:1, vol/vol), and stained with 0.5% crystal violet. The number of colonies was counted under the microscope.
Western blotting
Proteins from the cells were extracted in radioimmunoprecipitation assay buffer (Beyotime, Shanghai, China). Total cellular protein concentrations were determined using a bicinchoninic acid assay kit (Beyotime). For nuclear extract, cells were washed, lysed, and centrifuged to remove the supernatants. The nuclear fractions were processed using the EpiQuik Nuclear Extraction Kit (Epigentek, Brooklyn, New York) following the manufacturer's instructions.
The whole-cell extracts and nuclear extracts (20 -30 g) were boiled with equal amounts of loading dye for 10 minutes and separated by 10% PAGE and then transferred onto nitrocellulose membranes (Hybond-ECL; GE HealthCare, Little Chalfont, United Kingdom). Membranes were blocked in PBS with 0.1% Tween 20 containing 5% nonfat milk for 1 hour and then incubated with primary and secondary antibodies in PBS with 0.1% Tween 20 containing 5% nonfat milk. The following primary antibodies at the indicated dilutions were used: APC, ␤-catenin, ␤-actin, and lamin A (1:1000; Abcam, Cambridge, United Kingdom) and c-Myc, cyclin D1, TCF-1, and LEF-1 (1: 500; Santa Cruz Biotechnology, Santa Cruz, California). Primary antibody incubations were kept overnight at 4°C. The membranes were then washed with wash buffer (1ϫ PBS and 0.01% Tween 20) and incubated with a 1:2000 dilution of horseradish peroxidase-conjugated antirabbit or antimouse secondary antibody. The membranes were washed with wash buffer and developed.
Tumor xenograft animal model
Male athymic nude mice were housed and manipulated according to the protocols approved by the Experimental Animal Center of Tongji University. For each mouse, 5 ϫ 10 6 miR-155-overexpressing TPC-1 cells were injected sc into the right scapulas in 100 l serum-free medium. After development of palpable tumor, the tumor volume was monitored every 5 days and assessed by measuring the 2 perpendicular dimensions using a caliper and the formula (a ϫ b 2 )/2, where a is the larger and b is the smaller dimension of the tumor. At 25 days after inoculation, the mice were killed and tumor weights were assessed. A portion of each tumor was selected for immunohistochemical staining for Ki67, Western blotting for APC and key components of the Wnt/␤-catenin pathway, and quantitative real-time PCR (qRT-PCR) analysis for miR-155.
Statistical analysis
Results are presented as mean Ϯ SD from a minimum of 3 replicates. Difference between groups was evaluated by SPSS version 13.0 statistical software with Student's t test when comparing only 2 groups or assessed by 1-way ANOVA when more than 2 groups were compared. For comparison of paired tissues, a paired Student's t test was used to determine the statistical significance. The relationship between APC and miR-155 expression was explored by Spearman's correlation. Differences were considered statistically significant at P Ͻ .05.
Results
miR-155 is frequently upregulated in human PTC tissues and cell lines
To verify miR-155 upregulation in PTC, we quantified the expression of miR-155 in 20 fresh-frozen PTC specimens and adjacent normal tissues. The results of qRT-PCR showed that the average expression levels of miR-155 was significantly higher in PTC tissues than adjacent normal tissues ( Figure 1A) . Consistently, significant upregulation of miR-155 was also observed in 4 hu- 
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man PTC cell lines (TPC-1, CGTH-W3, K1, and IHH-4) compared with the noncancerous human TECs ( Figure 1B ). Taken together, these results provide novel evidence for miR-155 upregulation in human PTC tissues and cell lines.
miR-155 promotes PTC cell growth in vitro
To determine whether miR-155 regulates PTC cell growth, we first established miR-155 overexpression models in TPC-1 and CGTH-W3 cells infected with lentiviral vectors carrying the miR-155 gene. Increased expression of miR-155 upon infection in these PTC cell lines was confirmed by qRT-PCR (Figure 2A) . We then used these cells to determine their growth curve and colonyformation capacity. As shown in Figure 2 , B and C, overexpression of miR-155 significantly increased cell growth and colony formation in TPC-1 and CGTH-W3 cell lines compared with their corresponding controls. In contrast, miR-155 knockdown resulted in decreased cell growth and colony-formation capacity ( Figure 2D ). Taken together, these results suggest that miR-155 can promote cell growth and colonogenic potential in TPC-1 and CGTH-W3 cells.
miR-155 directly targets APC 3-UTR
To investigate the molecular mechanisms by which miR-155 promotes PTC cell growth, putative miR-155 targets were predicted using target prediction programs, such as TargetScan and miRanda. Our analysis revealed that APC was a potential target of miR-155. The 3Ј-UTR of APC mRNA contains a complementary site for the seed region of miR-155 ( Figure 3A ). To determine whether APC is a direct target of miR-155, the APC 3Ј-UTR and the mutant containing the miR-155 binding sites were subcloned into a reporter vector downstream of the luciferase gene. Luciferase reporter assays showed that the relative luciferase activity of the reporter that contained wild-type 3Ј-UTR of APC mRNA was significantly decreased in miR-155-overexpressing cells compared with control cells. However, mutation of the predicted binding site of miR-155 on the APC 3Ј-UTR rescued the luciferase activity ( Figure 3B) . Furthermore, the results of qRT-PCR and Western blotting showed that overexpression of miR-155 significantly decreased the levels of APC, whereas miR-155 knockdown prevented miR-155-induced reduction of APC mRNA and protein ( Figure 3 , C and D). Taken together, these results support the bioinformatics predictions indicating APC 3Ј-UTR as a direct target of miR-155.
APC is involved in miR-155-induced growth promotion in PTC cells
To investigate whether APC serves as a critical mediator of miR- 155's role in PTC cells, we performed loss-of-function and gain-of-function studies. First, we knocked down APC using specific RNA interference in TPC-1 cells. As shown in Figure 4A , siRNA against APC significantly promoted cell growth, which is similar to those induced by miR-155. Subsequently, we evaluated whether overexpression of APC could abolish the promotive effect of miR-155. TPC-1 cells stably overexpressing miR-155 were transfected with APC plasmids lacking 3Ј-UTR. We showed that APC overexpression significantly abolished miR-155-induced cell growth ( Figure 4B ). These results demonstrate that APC is a functional target of miR-155. . Furthermore, we analyzed the correlation between APC level and miR-155 expression in the same patients. As shown in Figure 4E , when the relative expression levels of APC were plotted against that of miR-155 in each patient, a significant inverse correlation was observed (P ϭ .007; R ϭ Ϫ0.805).
miR-155 activates the Wnt/␤-catenin pathway
Given that APC is implicated in ␤-catenin phosphorylation/degradation (28), we examined the expression levels of total ␤-catenin and nuclear ␤-catenin in PTC cells with miR-155 overexpression. As depicted in Figure 3D , a marked increase in total ␤-catenin and nuclear ␤-catenin expression was found. We then sought to determine whether miR-155 could regulate Wnt/␤-catenin signaling. TPC-1 and CGTH-W3 cells were transiently transfected with the Wnt signaling reporter TOPFlash or the negative control FOPFlash, along with miR-155 or miR control. We found that TCF/LEF transcriptional activity was significantly increased in miR-155-overexpressing cells, whereas this effect could be inhibited by anti-miR-155 ( Figure 5A ; the basal activity of TOPFlash/FOPFlash is shown in Supplemental Figure 2A ), indicating that Wnt/ ␤-catenin signaling is altered by miR-155. The same assay was performed on TECs, and we found further evidence to support our claims (Supplemental Figure 2) . To further investigate the functional role of the increased ␤-catenin induced by miR-155 overexpression, we performed lossof-function analyses by silencing ␤-catenin in miR-155-overexpressing TPC-1 cells. We found that silencing of ␤-catenin prevented miR-155-induced cell viability and colony-formation capacity ( Figure 5B ). These results further indicate that miR-155 promotes cell growth by activating Wnt/␤-catenin signaling. To further investigate the relationship between miR-155 and Wnt/␤-catenin signaling in PTC formation, we analyzed the protein levels of ␤-catenin in the same samples as Figure 4C . As depicted in Figure 5C and Supplemental Figure 3 , ␤-catenin expres- Figure 4C identified increased ␤-catenin expression in PTC. All assays were performed in triplicate. Data are presented as means Ϯ SD.
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sion was significantly higher in PTC tissues compared with adjacent normal tissues.
miR-155 overexpression promotes tumor growth of PTC cells in nude mice
To further investigate the role of miR-155 on promotion of tumor growth in vivo, miR-155-overexpressing and control TPC-1 cells were injected sc into the right scapula of each mouse (n ϭ 5). Although tumors formed in scapulas inoculated with either miR-155-overexpressing or control cells, the tumor growth of the miR-155-overexpressing tumors was significantly promoted ( Figure  6A ). The average tumor volume of the miR-155-overexpressing tumors was higher compared with control tumors ( Figure 6B ). Immunohistochemistry for Ki67 and prolif- 
miR-155 regulates
Wnt/␤-catenin signaling downstream target genes Finally, we examined the effect of miR-155 on the expression of c-Myc, cyclin D1, TCF-1, and LEF-1, which are major downstream genes of Wnt/ ␤-catenin signaling implicated in tumor growth. As shown in Figure 6F , the levels of these molecules were all increased in TPC-1 and CGTH-W3 cells stably overexpressing miR-155 in vitro. Consistently, the levels of all 4 molecules described above were also increased in miR-155-overexpressing tumors ( Figure 6G ). These findings indicate that miR-155 enhances the expression of Wnt/␤-catenin downstream genes in human PTC cells.
Discussion
The upregulation of miR-155 has been observed frequently in PTCs (22, 23) . However, to date, the relationship between miR-155 and PTC was not fully understood. In this study, we demonstrated for the first time that miR-155 promotes tumorigenesis in PTC by targeting a novel target, APC, which results in activation of Wnt/␤-catenin signaling.
A growing body of evidence strongly supports the substantial role that miR-155 plays in tumorigenesis and progression. miR-155 is overexpressed in many human cancers, including B cell lymphoma and carcinomas of the colon, breast, lung, and ovary (29 -31) . Supporting the role of miR-155 as an oncomiR is the finding that Emmu-miR-155 transgenic mice develop B cell malignancy (32) . Moreover, miR-155 represses tumor protein 53-induced nuclear protein 1 (TP53NP1), resulting in pancreatic tumor development (33) . Loss-of-function experi- ments conducted in several cancer models determined a role for miR-155 in tumor cell proliferation, migration, and invasion (20, 34) . To our knowledge, our study is the first to report a role for miR-155 in PTC.
As is well known, aberrant miRNA expression is closely related to the changes of cell morphology and function. In our study, we found that miR-155 is overexpressed at levels of 20-to 30-fold, but only an ϳ2-fold increase in growth and colony formation is observed. However, as this study (35) has shown, miRNAs in cancer cells show dynamic changes at levels of 20-to 40-fold, which doesn't mean that the cell morphology and function also show the same dynamic changes, and only ϳ1-to 4-fold change in growth and colony formation is observed. Furthermore, this is already significantly changes in cell growth and colony formation increased 1ϳ4-fold. Thus, our results suggest that miR-155 plays an important role in human PTC cell growth.
To date, several targets of miR-155 have been identified, such as SHIP, C/EBP␤ (33), FOXO3 (34), RHOA, MSH2, MSH6, MLH1, SOCS1 (36) , and CK1␣ (21) . On the basis of bioinformatics analysis, we further predicted several additional miR-155 targets, including APC, GSK-3␤ and CK1␣. Our present experimental results confirmed that APC is a functional target of miR-155 in PTC cells. There are several lines of evidence to support this. First, miR-155 overexpression significantly downregulated APC by directly targeting the 3Ј-UTR of APC mRNA, confirmed using luciferase-reporter-gene assays. This effect was largely eliminated when the sites in APC 3Ј-UTR targeted by miR-155 were mutated. Morever, both mRNA and protein of APC were significantly decreased in miR-155-overexpressing cells. We further found that knockdown of APC promoted cell growth similar to the phenotypes induced by miR-155 restoration, whereas APC overexpression could abolish the growthpromotive effect of miR-155. These results strongly suggested that miR-155-induced cell growth was partly mediated by repressing APC expression. It is worth noting that GSK-3␤ and CK1␣ are another 2 potential targets predicted by TargetScan. However, our results showed that overexpression of miR-155 did not affect GSK3␤ and CK1␣ expression in TPC-1 and CGTH-W3 cells (data not shown). Moreover, the reporter assay also showed that miR-155 did not repress the luciferase expression of pGL3-GSK3␤ 3Ј-UTR and pGL3-CK1␣ 3Ј-UTR (data not shown).
Our results further demonstrate that miR-155-mediated downregulation of APC leads to activation of Wnt/ ␤-catenin signaling in PTC cells. First, miR-155 overexpression caused ␤-catenin accumulation and nuclear translocation. Second, miR-155 overexpression increased TCF/LEF transcriptional activity, and this effect was blocked by anti-miR inhibition of miR-155. The importance of ␤-catenin in miR-155-induced tumor cell growth is also supported by the observation that siRNA depletion of ␤-catenin prevented miR-155-induced PTC viability and colony-formation capacity. Consistent with these findings, miR-155 overexpression was found to enhance the expression of several ␤-catenin downstream genes in PTC cells.
Upregulation of ␤-catenin occurs in a variety of cancers, namely colorectal, breast, and ovarian cancers (37, 38) . Mutations that activate ␤-catenin occur late in thyroid tumor progression, being detected in undifferentiated (anaplastic) thyroid carcinomas (39) . Increased free ␤-catenin pools have been observed in thyroid carcinomas secondary to reduced E-cadherin expression (40) . However, the exact mechanism for ␤-catenin activation in PTC has not been completely defined. Our findings in this study demonstrate a key role of miR-155 for ␤-catenin activation in human PTC cells. This finding is noteworthy, given that miR-155 is commonly upregulated in human PTC and that ␤-catenin is a key molecule implicated in tumorigenesis in PTC. Thus, miR-155 overexpression is a new mechanism that activates ␤-catenin in human PTC, and this pathway may play an important role in tumorigenesis of PTC.
This study identified miR-155 as an oncomiR in human PTC by targeting APC, consequently resulting in activation of Wnt/␤-catenin signaling and driving PTC cell growth. Our findings suggest that miR-155 may be a potential target for future prevention and treatment of human PTC.
